SEC Form 4
Oruka Therapeutics, Inc. (ORKA) insider trading
In the 12 months to Oct 26, 2026, 7 ORKA insiders reported open-market sales of $336.6M across 32 filings; no open-market purchases were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $336.6M
- 32 filings · 7 insiders
- Open-market purchases
- $0
- 0 filings
- Pre-arranged sales (10b5-1)
- 31 of 32
- $36.6M of $336.6M sold (11%)
Who traded ORKA, and when
- Sale
- Sale, pre-arranged (10b5-1)
ORKA daily close from Oct 27, 2025 to Oct 26, 2026, between $26.19 and $113.08, last $89.71. 32 sale and 0 purchase filings by 7 insiders, marked at their filing dates. Tomas Kiselak, Director: sold $300.0M across 1 filing, first filed Jul 1, 2026, last Jul 1, 2026. Lawrence Otto Klein, Chief Executive Officer: sold $9.0M across 2 filings, first filed Sep 1, 2026, last Oct 2, 2026. Carl Dambkowski, Director: sold $8.6M across 2 filings, first filed May 22, 2026, last Jun 12, 2026. Paul T. Quinlan, General Counsel: sold $7.3M across 3 filings, first filed Aug 14, 2026, last Oct 20, 2026. Arjun Agarwal, Senior Vice President, Finance: sold $5.0M across 8 filings, first filed May 18, 2026, last Oct 13, 2026. Joana Goncalves, Chief Medical Officer: sold $4.9M across 11 filings, first filed Dec 19, 2025, last Oct 15, 2026. Laura Lee Sandler, Chief Operating Officer: sold $1.8M across 5 filings, first filed Jan 2, 2026, last Sep 1, 2026.
Largest mark · tap a row for others
Tomas Kiselak · Director
Sale $300,014,406
3,553,410 shares at $84.43 avg
Filed Jul 1, 2026
Close on filing date $93.29
Tomas Kiselak · Director
Director
$300.0M soldLawrence Otto Klein · Chief Executive Officer
Chief Executive Officer
$9.0M soldCarl Dambkowski · Director
Director
$8.6M soldPaul T. Quinlan · General Counsel
General Counsel
$7.3M soldArjun Agarwal · Senior Vice President, Finance
Senior Vice President, Finance
$5.0M soldJoana Goncalves · Chief Medical Officer
Chief Medical Officer
$4.9M soldLaura Lee Sandler · Chief Operating Officer
Chief Operating Officer
$1.8M soldOpen-market trades
32 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Tomas Kiselak | Director | $300.0M | — | 1 | — | |
| Lawrence Otto Klein | Chief Executive Officer | $9.0M | — | 2 | 100% of sales | |
| Carl Dambkowski | Director | $8.6M | — | 2 | 100% of sales | |
| Paul T. Quinlan | General Counsel | $7.3M | — | 3 | 100% of sales | |
| Arjun Agarwal | Senior Vice President, Finance | $5.0M | — | 8 | 100% of sales | |
| Joana Goncalves | Chief Medical Officer | $4.9M | — | 11 | 100% of sales | |
| Laura Lee Sandler | Chief Operating Officer | $1.8M | — | 5 | 100% of sales |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Paul T. Quinlan General Counsel | SalePre-arranged (10b5-1) | 9,000 | $78.53 | $706.7K | 38,095 | |
traded | Joana Goncalves Chief Medical Officer | SalePre-arranged (10b5-1) | 7,000 | $74.81 | $523.6K | 35,918 | |
traded | Arjun Agarwal Senior Vice President, Finance | SalePre-arranged (10b5-1) | 9,999 | $80.60 | $805.9K | 18,477 | |
traded | Lawrence Otto Klein Chief Executive Officer | SalePre-arranged (10b5-1) | 25,000 | $83.62 | $2.1M | 931,882 | |
traded | Paul T. Quinlan General Counsel | SalePre-arranged (10b5-1) | 10,000 | $93.64 | $936.4K | 33,263 | |
traded | Arjun Agarwal Senior Vice President, Finance | SalePre-arranged (10b5-1) | 533 | $95.75 | $51.0K | 14,219 | |
traded | Arjun Agarwal Senior Vice President, Finance | SalePre-arranged (10b5-1) | 9,459 | $92.23 | $872.4K | 21,771 | |
traded | Joana Goncalves Chief Medical Officer | SalePre-arranged (10b5-1) | 7,000 | $91.93 | $643.5K | 32,818 | |
traded | Lawrence Otto Klein Chief Executive Officer | SalePre-arranged (10b5-1) | 75,000 | $91.83 | $6.9M | 993,976 | |
traded | Laura Lee Sandler Chief Operating Officer | SalePre-arranged (10b5-1) | 5,000 | $91.82 | $459.1K | 240,384 | |
traded | Joana Goncalves Chief Medical Officer | SalePre-arranged (10b5-1) | 7,000 | $111.84 | $782.9K | 35,198 | |
traded | Arjun Agarwal Senior Vice President, Finance | SalePre-arranged (10b5-1) | 10,000 | $106.66 | $1.1M | 17,670 | |
traded | Paul T. Quinlan General Counsel | SalePre-arranged (10b5-1) | 52,000 | $108.49 | $5.6M | 44,074 | |
traded | Joana Goncalves Chief Medical Officer | SalePre-arranged (10b5-1) | 7,000 | $86.28 | $603.9K | 33,018 | |
traded | Arjun Agarwal Senior Vice President, Finance | SalePre-arranged (10b5-1) | 9,999 | $84.63 | $846.2K | 25,011 | |
traded | Laura Lee Sandler Chief Operating Officer | SalePre-arranged (10b5-1) | 5,000 | $94.42 | $472.1K | 236,884 | |
traded | Tomas Kiselak Director | Sale | 3,553,410 | $84.43 | $300.0M | 1,131,954 | |
traded | Arjun Agarwal Senior Vice President, Finance | SalePre-arranged (10b5-1) | 1,587 | $80.95 | $128.5K | 15,312 | |
traded | Joana Goncalves Chief Medical Officer | SalePre-arranged (10b5-1) | 7,000 | $69.23 | $484.6K | 33,665 | |
traded | Arjun Agarwal Senior Vice President, Finance | SalePre-arranged (10b5-1) | 9,459 | $69.72 | $659.5K | 17,294 | |
traded | Carl Dambkowski Director | SalePre-arranged (10b5-1) | 35,000 | $70.13 | $2.5M | 38,743 | |
traded | Carl Dambkowski Director | SalePre-arranged (10b5-1) | 105,000 | $58.97 | $6.2M | 73,743 | |
traded | Arjun Agarwal Senior Vice President, Finance | SalePre-arranged (10b5-1) | 10,290 | $59.07 | $607.8K | 16,406 | |
traded | Joana Goncalves Chief Medical Officer | SalePre-arranged (10b5-1) | 7,000 | $61.85 | $432.9K | 35,577 | |
traded | Laura Lee Sandler Chief Operating Officer | SalePre-arranged (10b5-1) | 5,000 | $63.88 | $319.4K | 237,284 | |
traded | Joana Goncalves Chief Medical Officer | SalePre-arranged (10b5-1) | 7,000 | $66.12 | $462.8K | 36,150 | |
traded | Joana Goncalves Chief Medical Officer | SalePre-arranged (10b5-1) | 7,000 | $40.87 | $286.1K | 35,195 | |
traded | Laura Lee Sandler Chief Operating Officer | SalePre-arranged (10b5-1) | 5,000 | $33.56 | $167.8K | 240,259 | |
traded | Joana Goncalves Chief Medical Officer | SalePre-arranged (10b5-1) | 7,000 | $32.37 | $226.6K | 34,954 | |
traded | Joana Goncalves Chief Medical Officer | SalePre-arranged (10b5-1) | 7,000 | $31.81 | $222.7K | 4,137 | |
traded | Laura Lee Sandler Chief Operating Officer | SalePre-arranged (10b5-1) | 13,000 | $28.52 | $370.8K | 209,336 | |
traded | Joana Goncalves Chief Medical Officer | SalePre-arranged (10b5-1) | 7,000 | $30.61 | $214.3K | 1,518 |
GET /stocks/filings/vX/form-4?tickers=ORKA&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"ORKA"
],
"issuer_cik": "0000907654",
"owner_cik": "0001333277",
"accession_number": "0000907654-26-000110",
"form_type": "4",
"filing_date": "2026-10-20",
"period_of_report": "2026-10-20",
"issuer_name": "Oruka Therapeutics, Inc.",
"issuer_trading_symbol": "ORKA",
"owner_name": "Quinlan Paul T",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "General Counsel",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-20",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 1000,
"transaction_price_per_share": 77.205,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 37095,
"transaction_value": 77205,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026."
},
{
"id": "F4",
"description": "The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.70 to $77.57, inclusive."
}
]
},
{
"tickers": [
"ORKA"
],
"issuer_cik": "0000907654",
"owner_cik": "0001333277",
"accession_number": "0000907654-26-000110",
"form_type": "4",
"filing_date": "2026-10-20",
"period_of_report": "2026-10-20",
"issuer_name": "Oruka Therapeutics, Inc.",
"issuer_trading_symbol": "ORKA",
"owner_name": "Quinlan Paul T",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "General Counsel",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-20",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 3000,
"transaction_price_per_share": 79.4912,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 29995,
"transaction_value": 238473.6,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026."
},
{
"id": "F6",
"description": "The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.21 to $79.72, inclusive."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 71 records
- Option exercises48 records
- Tax withholding (sold to cover)15 records
- Grants and awards6 records
- Other2 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
- Counted once
- When several owners (a fund and its partners, say) report the same trade, it's counted once. Corrected filings replace the originals.
Frequently asked questions
Has Oruka Therapeutics, Inc.'s CEO sold stock?
Yes. Lawrence Otto Klein (CEO) sold 100,000 shares ($9.0M) between Sep 2026 and Oct 2026, all under a pre-arranged 10b5-1 plan.
How current is ORKA’s insider data?
These are ORKA Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track ORKA insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for ORKA every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.